Download PDF
Thromb Haemost 2010; 104(06): 1286-1289
DOI: 10.1160/TH10-04-0239
Letters to the Editor
Schattauer GmbH

Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions

Young-Hoon Jeong
1   Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
,
Yongwhi Park
1   Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
,
In-Suk Kim
2   Department of Laboratory Medicine, Gyeongsang National University Hospital, Jinju, Korea
,
Seong-Eun Yun
1   Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
,
Min-Kyung Kang
1   Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
,
Seok-Jae Hwang
1   Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
,
Choong Hwan Kwak
1   Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
,
Jin-Yong Hwang
1   Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
› Author Affiliations
Further Information

Publication History

Received: 19 April 2010

Accepted after major revision: 27 August 2010

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Grines CL. Off-label use of drug-eluting stents putting it in perspective. J Am Coll Cardiol 2008; 51: 615-617.
    CrossrefPubMedGoogle Scholar
  • 2 Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30: 1964-1977.
    CrossrefPubMedGoogle Scholar
  • 3 Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation 2009; 119: 657-659.
    CrossrefPubMedGoogle Scholar
  • 4 Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007; 116: 1952-1965.
    CrossrefPubMedGoogle Scholar
  • 5 Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102: 7-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Hattori Y, Suzuki K, Tomizawa A. et al. Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Res 2009; 81: 133-139.
    CrossrefPubMedGoogle Scholar
  • 7 Lee SW, Park SW, Yun SC. et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-291.e1.
    CrossrefPubMedGoogle Scholar
  • 8 Lee BK, Lee SW, Park SW. et al. Effects of triple anti-platelet therapy with aspirin, clopidogrel and cilostazol on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 2007; 100: 610-614.
    CrossrefPubMedGoogle Scholar
  • 9 Hayashi H, Sudo T. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost 2009; 102: 327-335.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Kim IS, Jeong YH, Kang MK. et al. Correlation of high post-clopidogrel platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolys. 2010 ((please complete reference)).
    PubMedGoogle Scholar
  • 11 Von Beckerath N, Kastrati A, Wieczorek A. et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819.
    CrossrefPubMedGoogle Scholar
  • 12 Geisler T, Zürn C, Simonenko R. et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59-66.
    CrossrefPubMedGoogle Scholar
  • 13 Sibbing D, Morath T, Braun S. et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Wiviott SD, Braunwald E, McCabe CH. et al. TRITON-TIMI 38 Investigators.. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371: 1353-1363.
    CrossrefPubMedGoogle Scholar
  • 15 Lee SW, Park SW, Kim YH. et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008; 51: 1181-1187.
    CrossrefPubMedGoogle Scholar
  • 16 Ota H, Eto M, Ako J. et al. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol 2009; 53: 2298-2305.
    CrossrefPubMedGoogle Scholar
  • 17 Cuisset T, Cayla G, Frere C. et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 5: 325-329.
    PubMedGoogle Scholar
  • 18 Sibbing D, Schulz S, Braun S. et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
    CrossrefPubMedGoogle Scholar
  • 19 Hobson A, Curzen N. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting. Thromb Haemost 2009; 101: 23-30.
    Article in Thieme ConnectPubMedGoogle Scholar